Equities Analysts Issue Forecasts for OCUL FY2025 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Stock analysts at Chardan Capital issued their FY2025 earnings estimates for Ocular Therapeutix in a research report issued on Wednesday, October 15th. Chardan Capital analyst D. Gataulin forecasts that the biopharmaceutical company will post earnings per share of ($1.45) for the year. Chardan Capital has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. Chardan Capital also issued estimates for Ocular Therapeutix’s FY2026 earnings at ($0.99) EPS.

OCUL has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Wednesday, October 8th. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 2nd. Piper Sandler raised their target price on shares of Ocular Therapeutix from $21.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, October 3rd. JMP Securities raised their target price on shares of Ocular Therapeutix from $20.00 to $29.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 1st. Finally, Robert W. Baird raised their target price on shares of Ocular Therapeutix from $17.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, October 3rd. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.63.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $12.18 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.02. Ocular Therapeutix has a one year low of $5.78 and a one year high of $13.85. The company has a 50-day simple moving average of $12.23 and a two-hundred day simple moving average of $10.09. The firm has a market capitalization of $2.12 billion, a PE ratio of -9.52 and a beta of 1.45.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The company had revenue of $13.46 million during the quarter, compared to analysts’ expectations of $13.12 million. During the same quarter last year, the business earned ($0.26) earnings per share. The business’s quarterly revenue was down 17.7% on a year-over-year basis.

Insider Activity

In related news, insider Jeffrey S. Heier sold 10,502 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total transaction of $115,942.08. Following the completion of the sale, the insider owned 249,409 shares of the company’s stock, valued at $2,753,475.36. This trade represents a 4.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pravin Dugel sold 21,494 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $12.04, for a total transaction of $258,787.76. Following the sale, the insider directly owned 3,227,244 shares of the company’s stock, valued at $38,856,017.76. This trade represents a 0.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold 61,806 shares of company stock worth $727,648 over the last three months. 2.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ocular Therapeutix

Several institutional investors and hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in shares of Ocular Therapeutix by 44.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company’s stock valued at $38,116,000 after acquiring an additional 1,600,000 shares in the last quarter. Deltec Asset Management LLC increased its position in shares of Ocular Therapeutix by 2.9% during the second quarter. Deltec Asset Management LLC now owns 2,794,892 shares of the biopharmaceutical company’s stock valued at $25,937,000 after acquiring an additional 78,519 shares in the last quarter. Invesco Ltd. increased its position in shares of Ocular Therapeutix by 91.2% during the second quarter. Invesco Ltd. now owns 1,538,846 shares of the biopharmaceutical company’s stock valued at $14,280,000 after acquiring an additional 734,017 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in Ocular Therapeutix in the 1st quarter worth approximately $9,632,000. Finally, Raymond James Financial Inc. grew its position in Ocular Therapeutix by 142.8% in the 2nd quarter. Raymond James Financial Inc. now owns 884,381 shares of the biopharmaceutical company’s stock worth $8,207,000 after purchasing an additional 520,138 shares during the period. Institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.